NCT05411510 is a NA clinical trial of Densah bur in Maxillary Sinus Disease, sponsored by Ahmed Mohamed Said Rozeik.

Who is sponsoring NCT05411510?

NCT05411510 is sponsored by Ahmed Mohamed Said Rozeik.

What drugs are being tested in NCT05411510?

Interventions in NCT05411510: Densah bur.

What condition does NCT05411510 study?

NCT05411510 studies Maxillary Sinus Disease.

Is NCT05411510 still recruiting?

NCT05411510 is currently status unknown. Last updated 9 June 2022.

Last reviewed 2022-06-09 · How we verify

NCT05411510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Bone Height Gain Following Trans-crestal Sinus Floor Elevation

Status unknown NA Last updated 9 June 2022

What this trial tests

NA trial testing Densah bur in Maxillary Sinus Disease in 20 participants. Status unknown.

Timeline

20 August 2022

Primary endpoint
20 February 2023

20 December 2023

Quick facts

Lead sponsor	Ahmed Mohamed Said Rozeik
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	20 August 2022
Primary completion	20 February 2023
Estimated completion	20 December 2023
Sites	2 locations across Egypt

Drugs / interventions tested

Densah bur

Conditions studied

Maxillary Sinus Disease — all drugs for Maxillary Sinus Disease →

Sponsor

Ahmed Mohamed Said Rozeik

Who can join

Adults 23 to 60, any sex, with Maxillary Sinus Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Missing teeth usually result in functional and cosmetic deficits. Traditionally, they have been restored with dentures or fixed bridges. However, dental implants represent an excellent alternative which rely on the maintenance of a direct structural and functional connection between living bone and implant surface, which is termed osseointergration . When sufficient bone is available in maxilla, implant rehabilitation has shown high success rates of 84-92 %. Atrophy of the alveolar crest and pneumatization of the maxillary sinus limits the quality and quantity of residual bone, therefore complicating the placement of implants in the posterior maxillary area.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Densah bur

Trials testing the same drug.

NCT06677125 — Magnetic Mallet and Densah Bur for Crestal Sinus Left · NA · recruiting

Other recruiting trials for Maxillary Sinus Disease

Currently open trials in the same condition.

NCT06887582 — Crestal Sinus Lifting in Periodontally-Compromised Patients Utilizing Autologous Dentin Graft · NA · active not recruiting
NCT06556225 — Isolated Maxillary Sinus Lesions in Sohag University Hospital · recruiting
NCT06504888 — Do Penicillin-allergic Patients Presents a High Risk of Sinus Lift Failure · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05411510 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahmed Mohamed Said Rozeik
Last refreshed: 9 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05411510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing